Base Metals Investing Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
Base Metals Investing Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
Base Metals Investing Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
Base Metals Investing Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
base metals investing Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
base metals investing Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
Significant Gold Discoveries Continue at Golden Gate - Drilling Hits 253.0m @ 1.5 g/t Au from Surface and Open in all Directions Ending in Mineralisation
Detailed Ground Gravity, Magnetic and Radiometric Surveys Refine Priority REE Targets at Desert Star Projects, California, USA
